Bristol-Myers Squibb Co. elected Louis W. Sullivan to its boardof directors. Sullivan was U.S. Secretary of Health and HumanServices from 1989 until 1993, and is president of MorehouseSchool of Medicine in Atlanta. The company has also electedJohn D. Macomber to the board. Macomber is immediate past-president of the Export-Import Bank of the United States. Priorto heading the Export-Import Bank, he was chairman of J. D.Macomber & Co., a private investment and advisory firm.
Bio-Imaging Technologies Inc. of West Trenton, N.J., appointedWilliam J. Fitzpatrick president and chief operating officer.James J. Conklin will continue as chief executive officer andchairman. Fitzpatrick was general manager of Cottrell Ltd. ofEnglewood, Colo., a multidivision manufacturer of infection-control products.
SyStemix Inc. of Palo Alto, Calif., appointed James J. Muledirector of gene therapy. He is the senior investigator at theNational Cancer Institute and previously directed thepreclinical gene therapy program at the NCI's surgery branch.
Biorelease Technologies Inc., the operating subsidiary ofBiorelease Corp. of Salem, N.H., has appointed Sheldon E.Schwartz vice president, pharmaceutical development andmedical affairs. He has seven years of senior managementexperience with Bristol-Myers Squibb.
Macronex Inc. of Research Traingle Park, N.C., named Bradley J.Benson director of chemistry. He was director of proteinchemistry at Scios-Nova.
Calgene Inc. of Davis, Calif., appointed Donal L. Baeder to itsboard of directors. He was chairman and chief executive officerof Regency Group Inc., which specializes in acquisition andrestructuring of environmentally sensitive businesses.
Cor Therapeutics Inc. of South San Francisco, Calif., appointedLloyd Hollingsworth Smith Jr. to its board of directors. Smith isassociate dean of the school of medicine at the University ofCalifornia, San Francisco and was previously professor ofmedicine and chairman of UCSF's department of medicine.
Immunomedics Inc. of Morris Plains, N.J., named RichardMurawski vice president of operations. He was director ofoperations for Burroughs Wellcome's Rhode Islandbiotechnology manufacturing plant.
Alamar Biosciences Inc. of Sacramento, Calif., named Joseph L.Schocken to its board of directors. He was president ofBroadmark Capital Corp. and Broadmark Holdings Inc. .
Protein Design Labs Inc. of Mountain View, Calif., named PaulNadler, vice president, medical and regulatory affairs, andCorine K. Klingbeil director, preclinical development. Nadlerwas vice president, scientific planning and evaluation, forSandoz Research Institute. Klingbeil was director of preclinicaldevelopment at Scios Nova.
(c) 1997 American Health Consultants. All rights reserved.